Indo Us Bio-Tech Ltd

Indo Us Bio-Tech Ltd announced its standalone unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the results in a meeting held on August 12, 2026. The financial results were also reviewed by the Audit Committee and the Statutory Auditors provided a limited review report with an unmodified opinion. The company operates primarily in Seed Cultivation, Processing & Trading.

Indo Us Bio-Tech Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved these results along with the limited review report from the auditor. The meeting was held on August 12, 2026, at the company's registered office in Ahmedabad. The company operates primarily in Seed Cultivation, Processing & Trading. No investor complaints were pending or received during the period under review.

Indo Us Bio-Tech Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026. Additionally, the board will discuss other corporate matters. The trading window for company insiders, which commenced on July 1, 2026, will remain closed until 48 hours after the dissemination of these financial results.

Indo Us Bio-Tech Ltd has clarified the effective date for the reconstitution of its Board Committees. The composition approved in the Board Meeting of July 10, 2026, is now effective from April 21, 2026, aligning with the appointment and resignation of Directors on that date. The filing details the revised composition of the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, with specific individuals appointed as Chairperson and Members for each. All other aspects of the July 10, 2026 outcome remain unchanged.

Indo Us Bio-Tech Ltd has announced the resignation of its statutory auditors, M/s. Gautam N Associates, effective June 15, 2026, citing administrative and operational restructuring. The company's Board of Directors, upon recommendation from the Audit Committee, has approved the appointment of M/s. Bhagat & Associates as the new statutory auditor, subject to shareholder approval. The new auditor's term will commence from the date of board approval until the conclusion of the next General Meeting. Details regarding both the outgoing and incoming auditors, as required by SEBI regulations, have been provided.

Indo Us Bio-Tech Ltd announced changes in its Board of Directors' committees following the resignation of Mrs. Nehaben Patel as Non-Executive Independent Director. The Board met on July 10, 2026, to approve these changes. Mrs. Hemanshi Darsh Soni was appointed as an Additional Director (Non-Executive, Independent), subject to shareholder approval. The reconstitution of the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee is effective from July 10, 2026, to ensure compliance with SEBI regulations and the Companies Act.

Indo Us Bio-Tech Ltd announced board meeting outcomes on July 3, 2026. The company is seeking shareholder approval via postal ballot for the regularization of Mrs. Hemanshi Darsh Soni's appointment as a Non-Executive Independent Director for a five-year term. Additionally, M/s. Bhagat & Associates have been appointed as Statutory Auditors, also subject to shareholder approval. The company has set June 26, 2026, as the cut-off date for e-voting eligibility. M/S Amrish Gandhi & Associates will act as the scrutinizer for the postal ballot process.

Indo Us Bio-Tech Ltd has announced the closure of its trading window for designated persons. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's internal code of conduct. The window will be shut from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Indo Us Bio-Tech Ltd announced the resignation of M/s. Gautam N Associates, Chartered Accountants, as its Statutory Auditor, effective June 15, 2026. The resignation was attributed to administrative and operational restructuring, with the company seeking to economize operations and appoint a local auditor. Following this, the Board of Directors, based on the Audit Committee's recommendation, approved the appointment of M/s. Bhagat & Associates, Chartered Accountants, as the new Statutory Auditor. This appointment is effective from June 15, 2026, and is subject to the approval of shareholders at the next General Meeting.

Indo Us Bio-Tech Ltd announced changes in its statutory and internal auditors following a Board of Directors meeting on June 16, 2026. M/s. Gautam N Associates resigned as Statutory Auditor, replaced by M/s. Bhagat & Associates, subject to shareholder approval. M/s. Raj Shah & Co. resigned as Internal Auditor, with M/s. J. M. Raval & Co. appointed as their replacement for a five-year term.